Preclinical studies have shown that low-grade RT combined with PD-1/PD-L1 inhibitors can improve the survival rate of mouse models of melanoma, renal cell carcinoma, breast cancer, and NSCLC and prevent tumor recurrence (75–77). Here, CD274 is linked to non-small cell lung carcinoma.